Diffuse Intrinsic Pontine Glioma

49

Pipeline Programs↗

20

Active Trials↗

26

Companies Involved↗

Diffuse Intrinsic Pontine Glioma is a moderately active landscape with 49 programs across 26 companies. The most active players are Roche, Bexion Pharmaceuticals, Inc., Johnson & Johnson. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

19/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Roche

2 programs

Bexion Pharmaceuticals, Inc.

1 program

Johnson & Johnson

1 program

Merck & Co.

1 program

EMD Serono

1 program

Bristol-Myers Squibb

1 program

Pipeline

Programs by Phase

Preclinical

No programs

Phase 128

Gemcitabine

Johnson & Johnson

Pembrolizumab

Merck & Co.

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Cilengitide

EMD Serono

Nivolumab

Bristol-Myers Squibb

Phase 214

Tovorafenib

Day One Biopharmaceuticals

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Bevacizumab

Bio-Thera Solutions

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Doxorubicin

Pfizer

Phase 33

Everolimus

Novartis

Nimotuzumab

Biotech Pharmaceutical Co., Ltd.

ONC201

Jazz Pharmaceuticals

Approved4

Abemaciclib

Eli Lilly

Vandetanib

Genzyme, a Sanofi Company

Panobinostat

SecuraBio

Imiquimod

Bausch Health Americas, Inc.

Analysis

Modality Breakdown

77%

Small molecule

36 of 47 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 98% of 58 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed20 · 40%

Recruiting10 · 20%

Active, not recruiting6 · 12%

Terminated5 · 10%

Unknown status3 · 6%

Not yet recruiting3 · 6%

Other3 · 6%

Clinical Trials

Trial Activity

50 trials

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Recruiting·Children's Oncology Group·Phase 1·NCT06894979·54 enrolled

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Recruiting·NNationwide Children's Hospital·Phase 2·NCT06838676·60 enrolled

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

Recruiting·—·Phase 1·NCT05717712·18 enrolled

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

Recruiting·SStanford University·Phase 1·NCT04196413·97 enrolled

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

Recruiting·TTata Memorial Centre·Phase 2·NCT04250064·40 enrolled

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Recruiting·SSeattle Children's Hospital·Phase 1·NCT04185038·90 enrolled

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05476939·433 enrolled

Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

Recruiting·—·Phase 1·NCT05717699·18 enrolled

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Recruiting·IInSightec·Phase 1/2·NCT05630209·10 enrolled

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05009992·360 enrolled

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Active, not recruiting·Children's Oncology Group·Phase 1·NCT04978727·35 enrolled

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02359565·71 enrolled

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Active, not recruiting·NNationwide Children's Hospital·Phase 1·NCT03605550·64 enrolled

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Active, not recruiting·SSeattle Children's Hospital·Phase 1·NCT05768880·72 enrolled

Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy

Active, not recruiting·HHospital Infantil Universitario Niño Jesús, Madrid, Spain·Phase 1/2·NCT04758533·13 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)